Clinical Impact of Personalized Physician’s Education and Remote Feedback Via a Digital Platform on Glycemic Control: Pilot Randomized Controlled Trial
BackgroundThe digital education platform Doctorvice (iKooB Inc.) offers face-to-face physician-patient education during outpatient clinic visits, remote glucose monitoring, and the delivery of educational messages, and is expected to be effective for personalized diabetes car...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2025-05-01
|
| Series: | JMIR mHealth and uHealth |
| Online Access: | https://mhealth.jmir.org/2025/1/e67151 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850037427034390528 |
|---|---|
| author | Jin Yu Joonyub Lee Yeoree Yang Eun Young Lee Seung-Hwan Lee Jae-Hyoung Cho |
| author_facet | Jin Yu Joonyub Lee Yeoree Yang Eun Young Lee Seung-Hwan Lee Jae-Hyoung Cho |
| author_sort | Jin Yu |
| collection | DOAJ |
| description |
BackgroundThe digital education platform Doctorvice (iKooB Inc.) offers face-to-face physician-patient education during outpatient clinic visits, remote glucose monitoring, and the delivery of educational messages, and is expected to be effective for personalized diabetes care.
ObjectiveThis study aims to evaluate the effectiveness of the digital education platform for diabetes care by comparing cases that included both face-to-face education and remote monitoring with those that included only face-to-face education.
MethodsThis was a randomized clinical study conducted at the Diabetes Center of Seoul St. Mary’s Hospital. Participants were aged ≥19 years and had glycated hemoglobin (HbA1c) levels between 7.5% and 9.5%. In the intervention group, physicians used the digital education platform to provide face-to-face education at enrollment and at the 3- and 6-month visits, along with remote monitoring during the first 3 months of the 6-month study period. The control group received conventional outpatient education. Both groups completed questionnaires—assessing satisfaction with diabetes treatment, diabetes-related stress, and adherence to diabetes medication—at the beginning and end of the study. The primary endpoint was the change in HbA1c levels.
ResultsA total of 66 participants were enrolled between August 1, 2022, and August 31, 2023. Of these, 26 in the intervention group and 30 in the control group were analyzed, excluding 10 participants who dropped out of the study. The mean baseline HbA1c levels were 8.3% (SD 0.6%) in the intervention group and 8.0% (SD 0.5%) in the control group. At the 3-month follow-up, mean HbA1c decreased by 0.5%-7.8% (SD 0.9%; P=.01) in the intervention group and by 0.2%-7.8% (SD 0.7%) in the control group. HbA1c levels substantially improved during the first 3 months with both face-to-face education and remote glucose monitoring. However, HbA1c tended to increase during the 3- to 6-month follow-up in the intervention group without the remote monitoring service. Satisfaction with diabetes treatment significantly improved at the end of the study compared with baseline in the intervention group (mean change +3.6 points; P=.006). Medication adherence improved in both groups, with no significant difference at 6 months (P=.59), although the intervention group showed a greater increase from baseline. Subgroup analysis indicated that the reduction in HbA1c was greater for patients with baseline HbA1c levels ≥8.0%, those aged ≥65 years, smokers, drinkers, and those with obesity in the intervention group.
ConclusionsThe digital education platform for personalized diabetes management may be beneficial for glycemic control in type 2 diabetes mellitus. Its effectiveness appears to be enhanced when physicians provide personalized face-to-face education combined with remote feedback.
Trial RegistrationClinical Research Information Service (CRiS) of Republic of Korea KCT0007953; https://cris.nih.go.kr/cris/search/detailSearch.do?seq=23507&search_page=L |
| format | Article |
| id | doaj-art-b1d0431020b540bc8670bcd2d22d671d |
| institution | DOAJ |
| issn | 2291-5222 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIR mHealth and uHealth |
| spelling | doaj-art-b1d0431020b540bc8670bcd2d22d671d2025-08-20T02:56:51ZengJMIR PublicationsJMIR mHealth and uHealth2291-52222025-05-0113e6715110.2196/67151Clinical Impact of Personalized Physician’s Education and Remote Feedback Via a Digital Platform on Glycemic Control: Pilot Randomized Controlled TrialJin Yuhttps://orcid.org/0000-0003-4967-9862Joonyub Leehttps://orcid.org/0000-0003-0533-9786Yeoree Yanghttps://orcid.org/0000-0003-0990-1502Eun Young Leehttps://orcid.org/0000-0002-4968-5026Seung-Hwan Leehttps://orcid.org/0000-0002-3964-3877Jae-Hyoung Chohttps://orcid.org/0000-0003-2235-8874 BackgroundThe digital education platform Doctorvice (iKooB Inc.) offers face-to-face physician-patient education during outpatient clinic visits, remote glucose monitoring, and the delivery of educational messages, and is expected to be effective for personalized diabetes care. ObjectiveThis study aims to evaluate the effectiveness of the digital education platform for diabetes care by comparing cases that included both face-to-face education and remote monitoring with those that included only face-to-face education. MethodsThis was a randomized clinical study conducted at the Diabetes Center of Seoul St. Mary’s Hospital. Participants were aged ≥19 years and had glycated hemoglobin (HbA1c) levels between 7.5% and 9.5%. In the intervention group, physicians used the digital education platform to provide face-to-face education at enrollment and at the 3- and 6-month visits, along with remote monitoring during the first 3 months of the 6-month study period. The control group received conventional outpatient education. Both groups completed questionnaires—assessing satisfaction with diabetes treatment, diabetes-related stress, and adherence to diabetes medication—at the beginning and end of the study. The primary endpoint was the change in HbA1c levels. ResultsA total of 66 participants were enrolled between August 1, 2022, and August 31, 2023. Of these, 26 in the intervention group and 30 in the control group were analyzed, excluding 10 participants who dropped out of the study. The mean baseline HbA1c levels were 8.3% (SD 0.6%) in the intervention group and 8.0% (SD 0.5%) in the control group. At the 3-month follow-up, mean HbA1c decreased by 0.5%-7.8% (SD 0.9%; P=.01) in the intervention group and by 0.2%-7.8% (SD 0.7%) in the control group. HbA1c levels substantially improved during the first 3 months with both face-to-face education and remote glucose monitoring. However, HbA1c tended to increase during the 3- to 6-month follow-up in the intervention group without the remote monitoring service. Satisfaction with diabetes treatment significantly improved at the end of the study compared with baseline in the intervention group (mean change +3.6 points; P=.006). Medication adherence improved in both groups, with no significant difference at 6 months (P=.59), although the intervention group showed a greater increase from baseline. Subgroup analysis indicated that the reduction in HbA1c was greater for patients with baseline HbA1c levels ≥8.0%, those aged ≥65 years, smokers, drinkers, and those with obesity in the intervention group. ConclusionsThe digital education platform for personalized diabetes management may be beneficial for glycemic control in type 2 diabetes mellitus. Its effectiveness appears to be enhanced when physicians provide personalized face-to-face education combined with remote feedback. Trial RegistrationClinical Research Information Service (CRiS) of Republic of Korea KCT0007953; https://cris.nih.go.kr/cris/search/detailSearch.do?seq=23507&search_page=Lhttps://mhealth.jmir.org/2025/1/e67151 |
| spellingShingle | Jin Yu Joonyub Lee Yeoree Yang Eun Young Lee Seung-Hwan Lee Jae-Hyoung Cho Clinical Impact of Personalized Physician’s Education and Remote Feedback Via a Digital Platform on Glycemic Control: Pilot Randomized Controlled Trial JMIR mHealth and uHealth |
| title | Clinical Impact of Personalized Physician’s Education and Remote Feedback Via a Digital Platform on Glycemic Control: Pilot Randomized Controlled Trial |
| title_full | Clinical Impact of Personalized Physician’s Education and Remote Feedback Via a Digital Platform on Glycemic Control: Pilot Randomized Controlled Trial |
| title_fullStr | Clinical Impact of Personalized Physician’s Education and Remote Feedback Via a Digital Platform on Glycemic Control: Pilot Randomized Controlled Trial |
| title_full_unstemmed | Clinical Impact of Personalized Physician’s Education and Remote Feedback Via a Digital Platform on Glycemic Control: Pilot Randomized Controlled Trial |
| title_short | Clinical Impact of Personalized Physician’s Education and Remote Feedback Via a Digital Platform on Glycemic Control: Pilot Randomized Controlled Trial |
| title_sort | clinical impact of personalized physician s education and remote feedback via a digital platform on glycemic control pilot randomized controlled trial |
| url | https://mhealth.jmir.org/2025/1/e67151 |
| work_keys_str_mv | AT jinyu clinicalimpactofpersonalizedphysicianseducationandremotefeedbackviaadigitalplatformonglycemiccontrolpilotrandomizedcontrolledtrial AT joonyublee clinicalimpactofpersonalizedphysicianseducationandremotefeedbackviaadigitalplatformonglycemiccontrolpilotrandomizedcontrolledtrial AT yeoreeyang clinicalimpactofpersonalizedphysicianseducationandremotefeedbackviaadigitalplatformonglycemiccontrolpilotrandomizedcontrolledtrial AT eunyounglee clinicalimpactofpersonalizedphysicianseducationandremotefeedbackviaadigitalplatformonglycemiccontrolpilotrandomizedcontrolledtrial AT seunghwanlee clinicalimpactofpersonalizedphysicianseducationandremotefeedbackviaadigitalplatformonglycemiccontrolpilotrandomizedcontrolledtrial AT jaehyoungcho clinicalimpactofpersonalizedphysicianseducationandremotefeedbackviaadigitalplatformonglycemiccontrolpilotrandomizedcontrolledtrial |